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Background. Mesangial cells (MC) are known to secrete various
vasoactive substances that may control endothelial and epithelial
cell growth. Therefore, the cell-cell interactions among these cells
may be important in the control of renal function. However, the
exact mechanisms of maintaining the cell-cell interactions are not
yet understood. We have focused on the role of hepatocyte growth
factor (HGF) in the regulation of cell-cell interactions, since HGF
has many protective functions in the kidney. To investigate the
role of HGF in renal injury, we examined (1) the effects of HGF
on epithelial injury induced by serum deprivation, and (2) the role
of local HGF production in the maintenance of renal structure.
Methods. Apoptotic changes in epithelial cells were assessed by
nuclear morphology and DNA fragmentation assay. Transfection
of human HGF vector into epithelial cells was performed by a
highly efficient viral-liposome method. The effects of secreted
HGF on the growth of renal cells were examined using a
co-culture system.
Results. The addition of recombinant HGF (rHGF) stimulated
the growth of rat and porcine epithelial cells. Moreover, the
decrease in number of epithelial cells by serum deprivation was
significantly attenuated by rHGF. Interestingly, apoptotic changes
in epithelial cells induced by serum deprivation were also signif-
icantly attenuated by rHGF (P , 0.01). As a model of gene
therapy, the effects of overexpression of human HGF gene in
epithelial cells on apoptosis induced by serum deprivation were
examined. Transfection of human HGF vector into epithelial cells
also attenuated epithelial cell death induced by serum deprivation
through the inhibition of apoptosis, accompanied by increased
HGF production (P , 0.01). In addition, HGF also prevented
endothelial injury induced by tumor necrosis factor-a and dexa-
methasone. Given the presence of a local HGF system, we
measured local HGF secreted from renal cells. Immunoreactive
HGF was observed in the conditioned medium of MC, but not
epithelial cells, while the specific receptor of HGF, c-met, was
expressed in epithelial cells. Of importance, co-culture of MC with
epithelial cells resulted in a significant increase in number of
epithelial cells, which was significantly abolished by neutralizing
anti-HGF antibody.
Conclusions. Overall, these results demonstrate that local pro-
duction of HGF in MC may maintain the growth of epithelial and
endothelial cells through its anti-apoptotic action.
Mesangial cells secrete various growth factors and cyto-
kines that may regulate endothelial and epithelial cells.
Hepatocyte growth factor (HGF) was initially identified as
the most potent growth factor for hepatocytes [1, 2], and is
well known as a mesenchyme-derived pleiotropic factor
that regulates cell growth, cell motility, and morphogenesis
of various types of cells. HGF is also considered to be a
humoral mediator of epithelial-mesenchymal interactions
responsible for morphogenic tissue interactions during
embryonic development and organogenesis [3–5]. Of im-
portance, recent studies suggest that HGF has many ac-
tions on the cells of other target organs including the
kidney [6–9]. Acute renal failure is often reversible, and
recovery depends on mitogensis, motogensis and morpho-
gensis (tubular formation) of renal epithelial cells. Thus,
rapid regeneration of renal epithelial cells might be impor-
tant for the treatment of acute renal failure. HGF enhances
renal regeneration and suppresses the onset of acute renal
failure caused by renal toxins, renal ischemia, or unilateral
nephrectomy [6–9]. For example, administration of recom-
binant HGF (rHGF) promoted the regeneration of epithe-
lial cells injured by anti-tumor drugs [7]. HGF mRNA and
blood HGF levels increase markedly after unilateral ne-
phrectomy and in acute renal failure [8, 9]. However, little
is known about the local HGF system in the kidney and the
mechanisms of the protective actions of HGF in renal cells.
As it is apparent that cell-cell interactions among these
cells are important in the control of renal function, we
wanted to determine the exact mechanisms of maintaining
the cell-cell interactions in the kidney, given the presence
of a local renal HGF system. On the other hand, it has been
hypothesized that endothelial cells may also modulate
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mesangial cell growth, because many anti-proliferative fac-
tors such as nitric oxide (NO) and vascular natriuretic
peptides are secreted by endothelial cells [10–12]. It is
apparent that dysfunction of endothelial and/or epithelial
cells may promote abnormal mesangial cell growth, for
example, in glomerulonephritis [13–16]. Previously, we
have reported that local HGF production by mesangial
cells maintains the growth of glomerular endothelial cells
[17], suggesting the potential contribution of HGF to the
maintenance of renal function. In the current study, we
examined whether: (1) HGF has a protective role in
epithelial and endothelial injury, and (2) HGF has anti-




Cell culture. Rat mesangial cells were donated by Kirin
Brewery Co., Ltd. (Tokyo, Japan) [17]. These cells were
used within passages 5 to 7. Rat epithelial cells (NRK-52E)
and porcine tubular epithelial cells (LLC-PK1) were pur-
chased from ATCC (American Tissue Culture Collection).
Rat mesangial and NRK-52E cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum, 100 U/ml penicillin and
100 mg/ml streptomycin. LLC-PK1 cells were maintained in
Medium 199 supplemented with 5% fetal calf serum, 100
U/ml penicillin and 100 mg/ml streptomycin. Human endo-
thelial cells (passage 5) were obtained from Clonetics Corp.
(San Diego, CA, USA), and cultured in modified
MCDB131 medium supplemented with 5% fetal calf se-
rum, 100 U/ml penicillin, 100 mg/ml streptomycin, 10 ng/ml
epidermal growth factor, 2 ng/ml basic fibroblast growth
factor (bFGF) and 1 mM dexamethasone in the standard
fashion [18]. Cells were incubated at 37°C in a humidified
atmosphere of 95% air-5% CO2 with media changes every
two days. These cells showed the specific characteristics of
mesangial, epithelial and endothelial cells, respectively, on
immunohistochemical examination and morphological ob-
servations.
Cell counting assay
In the preparation of experiments for determination of
cell count, the cells were grown to 70% confluence in
96-well culture plates (Becton Dickinson Co., Belgium).
After cells reached 70% confluence, the medium was
changed to fresh, defined serum-free medium (DSF). DSF
containing insulin (5 3 1027 M), transferrin (5 mg/ml), and
ascorbate (0.2 mM) maintains cells in a non-catabolic state,
as previously reported [19]. The cells were then incubated
overnight. On day 1, the medium was again changed to
fresh DSF containing HGF (10 ng/ml), vascular endothelial
cell growth factor (VEGF) (10 ng/ml) or vehicle. On day 3,
the medium was again changed to fresh DSF containing
growth factor or vehicle. On day 4, an index of cell
proliferation was determined using WST-cell counting kit
(Wako, Osaka, Japan). Tetrazolium salt has been used to
develop a quantitative colorimetric assay for cell growth.
The assay detects living, but not dead cells. For this
purpose, 3-(4,5-dimethylthiazol-2-yl)-2,5,-diphenyl tetrazo-
lium bromide (MTT) is widely used [20]. In this study, we
used an alternative of MTT, that is, sulfonated tetrazolium
salt, 4-[3-(4-iodophenyl]-2-(4-nitrophenyl)-2H-5-tetrazo-
lio]-1,3-benzene disulfonate (WST-1), since this compound
produces a highly water-soluble formazan dye that makes
the assay procedure easier to perform [20]. The plates were
read on a Bio-Rad Model 3550 Microplate reader, using
a test wavelength of 450 nm, and a reference wavelength
of 650 nm. We confirmed that serum-stimulated increase
in cell number is associated with increased absorbance at
450 nm.
Treatment by serum deprivation
In the preparation of experiments for determination of
cell death, epithelial cells were grown to confluence. After
cells reached confluence, the medium was changed to fresh,
defined serum-free (DSF) medium containing HGF, basic
fibroblast growth factor (bFGF), VEGF, or vehicle. The
cells were then incubated. Every two days the medium was
changed to fresh DSF medium containing HGF, bFGF,
VEGF, or vehicle. On days 2 and 4, an index of cell
proliferation was determined as described above.
Apoptotic cells induced by serum deprivation were also
counted at 48 and 96 hours. Cells to be analyzed for
apoptosis were stained with propium iodide (PI) and
Hoechst 33342, and viewed under fluorescence microscopy
as previously described [21–24]. Using both membrane-
permeable (H33342) and -impermeable (PI) dyes in the
assay allowed the determination of cell viability and plasma
membrane integrity, and an accounting for any non-apop-
totic toxic or necrotic death induced in the study groups.
Cells were seeded onto six-well dishes (Lab-Tek) and were
cultured in DSF medium for two days, after reaching
confluence. To stain the cells for DNA, cells were incu-
bated with Hoechst 33342 (5 mg/ml in PBS) for 20 minutes
at 37°C. The medium and a PBS rinse of the culture wells
were collected before brief addition and decantating of
trypsin/EDTA. Culture wells were incubated in residual
trypsin/EDTA for three minutes in humidified air at 37°C
to achieve maximal cell detachment before rinsing with
PBS and collection. The collected medium, including the
rinse and trypsinized cells, were pooled and collected by
centrifugation at 1000 rpm for five minutes at 4°C. Cell
pellets were resuspended in a small volume of serum-
containing medium with 5 mg/ml Hoechst 33342 and 1
mg/ml PI. An aliquot was placed on a glass slide, covered
with a glass coverslip, and viewed under fluorescence
microscopy. Individual nuclei were visualized at 3400 to
distinguish the normal uniform nuclear pattern from the
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characteristic condensed coalesced chromatin pattern of
apoptotic cells. For each sample, 300 cells were examined.
The number of apoptotic cells was counted under micros-
copy (magnification, 3100) in a blinded manner. The total
number of apoptotic cells in each section was summed and
expressed as a percentage of the total cell number. At least
ten individual sections were evaluated per slide. Samples
were coded so that the analysis was performed without
knowledge of which treatment each cells had received. The
reproducibility of the results was assessed. Intraobserver
variability was determined from triplicate measurements
performed by one observer for all sections. The mean 6 SD
difference among measurements made by the same ob-
server was 2.6 6 0.6%. Interobserver variability was deter-
mined from measurements of 10 randomly selected sec-
tions performed by a second observer in addition to the first
observer. The difference between measurements made by
the two observers was 3.0 6 0.8%. These observers were
blinded to other data concerning the cells, as well as to the
results of the other observer.
Also, we employed the measurement of cellular DNA
fragmentation using cellular DNA Fragmentation ELISA
kit (Boehringer Mannheim, Germany), to quantity apopto-
sis [25]. Cultured epithelial cells were incubated with 10 mM
BrdU overnight at 37°C in 5% CO2. At four days after
transfection, lysing solution containing BSA, EDTA, and
Tween 20 was added to each well. DNA fragments in 100 ml
cell lysate supernatant were tested by ELISA. The super-
natant was transferred to an anti-DNA-precoated microti-
ter plate and incubated for 60 minutes at 37°C. After
washing, the samples were denatured and fixed by micro-
wave irradiation for five minutes. After cooling the micro-
titer plate for 10 minutes at 220°C, anti-BrdU peroxidase-
conjugated solution was added and the plate was incubated
for 60 minutes at 37°C. Wells were again washed, TMB
substrate solution was added, and the plate was incubated
for 30 minutes at room temperature. Stopping solution (25
ml 1 M H2SO4) was then added to each well. Absorbance
was measured at 450 nm (reference wavelength, 690 nm).
Briefly, 10,000 apoptotic cells/well reflects absorbance 1.5
in the manufacturer’s recommended condition. The sensi-
tivity of DNA fragmentation ELISA assay is well correlated
with the results from the conventional 3H-thymidine based
DNA fragmentation assay. In our experimental conditions,
an increase in absorbance by 0.2 reflected an increase in the
cell number from 2,000 apoptotic cells/well.
Preparation of HVJ-liposomes
To produce an HGF expression vector, human HGF
cDNA (2.2 kb) was inserted into the Eco RI and Not I sites
of pUC-SRa expression vector plasmid. In this plasmid,
transcription of the HGF cDNA was under the control of
the SRa promoter [1, 26, 27]. We employed the hemagglu-
tinating virus of Japan (HVJ)-liposome method [27–29].
Briefly, phosphatidylserine, phosphatidylcholine, and cho-
lesterol were mixed in a weight ratio of 1:4.8:2 in tetrahy-
drofuran. The lipid mixture (10 mg) was deposited on the
sides of a flask by removal of the solvent in a rotary
evaporator. High mobility group (HMG) 1 nuclear protein
(96 mg), purified from calf thymus, was mixed with plasmid
DNA (300 mg) in 200 ml balanced salt solution (BSS; 137
mM NaCl, 5.4 mM KCl, 10 mM Tris-HCl, pH 7.6) at 20°C for
one hour, and then added to the dried lipid. Liposome-
DNA-HMG 1 complex suspension was mixed by vortex,
sonication for three seconds, and shaking for 30 minutes.
Purified HVJ (Z strain) was inactivated by UV irradiation
(110 erg/mm2/sec) for three minutes immediately prior to
use. The liposome suspension (0.5 ml, containing 10 mg
lipid) was mixed with HVJ (20,000 hemagglutinating units)
in a total volume of 4 ml BSS. The mixture was incubated
at 4°C for 10 minutes and then for 30 minutes with gentle
shaking at 37°C. Free HVJ was removed from the HVJ-
liposomes by sucrose density gradient centrifugation. The
top layer of the sucrose gradient containing the HVJ-
liposome-DNA complex was collected and used immedi-
ately.
Epithelial cells (1 3 106) were seeded onto six-well plates
(Corning, NY, USA) and grown to 80% confluence. Cells
were washed three times with BSS containing 2 mM CaCl2
and then incubated with 1 ml HVJ-liposomes-DNA com-
plex (2.5 mg lipid and 10 mg encapsulated DNA) at 4°C for
five minutes followed by 37°C for 30 minutes (total, 35
min). The cells were then washed and fed fresh medium
containing 10% calf serum and placed in a CO2 incubator.
To document the successful transfection of cells, we exam-
ined the production of HGF. Twenty-four hours after
transfection, the medium was changed to fresh DSF and
the cells were incubated for an additional 48 hours. To
study the release of HGF, transfected cells (48 hr post-
transfection) were washed and fed with 1 ml DSF. Twenty-
four hours later, conditioned medium was collected, cen-
trifuged at 600 g for 10 minutes and stored at 220°C [28].
The concentration of HGF in the medium was determined
by enzyme-immunoassay using anti- human HGF antibod-
ies [27, 30]. On day 4, an index of cell proliferation was
determined using WST-cell counting kit (Wako). The
number of apoptotic cells was also counted in a blinded
manner.
Reverse transcription-polymerase chain reaction
RNA was extracted from each cell type by RNAzol
(Tel-Test Inc., TX, USA), after cells reached confluence
under serum stimulation. The level of HGF receptor
(c-met) mRNA was measured by reverse transcription-
polymerase chain reaction (RT-PCR) [31]. The 59 primer
2788-2811 complementary to the rat c-met gene was 59-
CAG-TGA-TGA-TCT-CAA-TGG-GCA-AT-39; the 39
primer 3492-3504 was 59-AAT-GCC-CTC-TTC-CTA-
TGA-CTT-C-39CAA-TGG-GGG. Extreme care was taken
to avoid contamination of tissue samples with trace
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amounts of experimental RNA. Aliquots of RNA (0.5 mg)
derived from cultured cells were amplified simultaneously
by PCR (35 cycles), with the same reagents, by individuals
who were blinded to the identity of the samples, and
compared with a negative control (primers without RNA).
Amplification products were electrophoresed through 2%
agarose gel and stained with ethidium bromide. To ensure
that the RT-PCR amplified product reflects transcribed
c-met RNA without significant DNA contamination, RNA
samples treated with RNase A or amplified without reverse
transcriptase were amplified simultaneously as negative
controls. These samples did not result in a visual band.
Moreover, PCR products were cut by restriction enzymes,
and the fragments were identical to the theoretical bands.
At least three aliquots of each DNA and RNA sample were
subjected to separate PCR amplification in all experiments.
Measurement of hepatocyte growth factor in conditioned
medium
Rat mesangial and epithelial cells were seeded on six-
well plates (Corning) at a density of 5 3 104 cells/cm2 and
cultured for 24 hours. After replacing the medium with
fresh DSF and following culture for 24 hours, the concen-
tration of HGF in the medium was determined by enzyme-
immunoassay using anti-rat HGF antibody. This EIA spe-
cifically detects rat HGF, because of lack of cross-reactivity
against human HGF [18, 27, 30, 31].
Co-culture of mesangial cells with epithelial cells
Cells to be co-cultured were seeded onto cell culture
inserts (3.0 mM pore size; Becton Dickinson & Company,
Belgium) and grown in 10% DMEM. Cells were seeded
onto six-well plates (Becton Dickinson), maintained in 10%
fetal calf serum and placed in DSF medium for 48 hours
following 80% confluence. At confluence, the inserts con-
taining co-cultured cells were put into the wells containing
the quiescent cells [17, 28]. Epithelial cells in the lower well
were co-cultured for 48 hours with mesangial cells in DSF
with 0.5% serum, and cell numbers were assessed by cell
counting assay.
Effect of neutralizing anti-hepatocyte growth factor
antibody
For each of the antibodies, the IgG fraction (purified
with protein A-agarose) was able to neutralize a biological
activity of 10 ng/ml HGF, at a concentration of 10 mg/ml
[17]. Normal rabbit serum IgG fraction (10 mg/ml) was
employed as a control. The number of epithelial cells was
examined in two groups: group 1, with anti-rat HGF
antibody (final 10 mg/ml), and group 2, with normal IgG
(final 10 mg/ml). Neutralizing anti-rat HGF antibody can
attenuate only the effects of rat and murine HGF, but not
human, bovine or porcine HGF.
Determination of DNA and RNA synthesis
Endothelial cells were seeded onto 24-well tissue culture
plates (Corning). At confluence, endothelial cells were
rendered quiescent by incubation for 48 hours in DMEM
with 0.5% fetal bovine serum. Relative rates of DNA and
RNA synthesis were assessed by determination of 3H-
thymidine or uridine incorporation into trichloroacetic acid
(TCA)-precipitable material over the next 24 hours, respec-
tively. HGF or vehicle (fresh DSF containing 0.1% bovine
serum albumin) was added 12 hours prior to the addition of
3H-thymidine or uridine. Twenty-four hours after the ad-
dition of 3H-thymidine or uridine, the cells were washed
twice with cold PBS, twice with 10% (wt/vol) cold TCA and
incubated with 10% TCA at 4°C for 30 minutes. Cells were
rinsed in ethanol (95%) and dissolved in 0.25 N NaOH at
4°C for three hours, neutralized, and the radioactivity was
determined by liquid scintillation spectrometry [28].
Fig. 1. Effect of exogenously added rat recombinant hepatocyte growth
factor (HGF) on numbers of rat epithelial cells (NRK-52E) (A) and
porcine tubular epithelial cells (LLC-PK1) (B). N 5 8 per group.
Abbreviations are: DSF, vehicle added to cells; HGF, rat rHGF (10 ng/ml)
added to cells; VEGF, recombinant vascular endothelial growth factor (10
ng/ml) added to cells. **P , 0.01 versus DSF.
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Materials
Human and rat recombinant HGF were purified from
the culture medium of Chinese hamster ovary cells or
C-127 cells, respectively, transfected with expression plas-
mid containing human or rat HGF cDNA [1, 26]. VEGF
and bFGF were obtained from Biosource (Camarillo, CA,
USA).
Statistical analysis
All values are expressed as mean 6 SEM. Analysis of
variance with subsequent Bonferroni’s test was employed
to determine the significance of differences in multiple
comparisons. Values of P , 0.05 were considered statisti-
cally significant.
RESULTS
Effect of recombinant hepatocyte growth factor on
epithelial cell death induced by serum deprivation
First, the effect of rat recombinant HGF on the growth
of rat epithelial cells (NRK-52E) was examined (Fig. 1a).
The addition of rHGF as well as VEGF stimulated growth
of epithelial cells. The specificity of the stimulatory effects
of HGF was confirmed by the blockade of cell growth by
anti-HGF specific antibody (data not shown). Similarly, rat
rHGF stimulated the growth of porcine tubular epithelial
cells (LLC-PK1; Fig. 1B). Previously, we have reported that
rat and human rHGF had no mitogenic actions on rat and
human mesangial cells, whereas rHGF could stimulate
growth of endothelial cells [17, 32, 33]. These results
indicate that HGF can exert stimulatory effects on growth
of epithelial and endothelial cells without replication of
mesangial cells. Next, we examined the effect of HGF
treatment on cell death induced by serum deprivation and
discovered that serum deprivation caused epithelial cell
death (Fig. 2). Twelve hours after serum deprivation, some
cells started to become round and eventually detached
from the plate, floating in the medium and leaving many
holes in the sheet of confluent cells (data not shown). The
floating cells could be recovered with the medium, and
neither attached onto a new plate nor proliferated. Consis-
tent with this morphological observation, the cell death rate
after serum deprivation was significantly increased at 96
hours, as shown in Figure 2. The addition of rHGF (10
ng/ml) resulted in partial attenuation of cell death medi-
ated by serum deprivation in a dose-dependent manner at
96 hours (Fig. 2). VEGF as well as bFGF also partially
prevented epithelial cell death induced by serum depriva-
tion treatment. Cell death injury due to serum deprivation
was predominant by apoptosis, consistent with the previous
reports [34, 35]. As shown in Figure 3A, morphological
studies demonstrated the typical features of apoptotic cells.
Indeed, serum deprivation resulted in a significant increase
in apoptotic epithelial cells as assessed by morphology (Fig.
3). Serum deprivation significantly increased the apoptotic
cells, which was abolished by addition of serum as assessed
by Hoechst staining (P , 0.01). Importantly, the addition of
rHGF also prevented apoptosis of epithelial cells induced
by serum deprivation in a dose-dependent manner both at
48 and 96 hours (Fig. 3). Similarly, bFGF as well as VEGF
prevented the apoptosis (P , 0.05) both at 48 and 96 hours.
Similar results were obtained using PI staining (data not
shown). These results were confirmed by the measurement
of DNA fragmentation (Fig. 4). Consistent with nuclear
staining, the addition of rHGF significantly decreased the
DNA fragmentation index both at 10 and 100 ng/ml of
concentration under serum free conditions (P , 0.01).
Fig. 2. Effects of exogenously added hepatocyte
growth factor (HGF), vascular endothelial
growth factor (VEGF) and basic fibroblast
growth factor (bFGF) on epithelial cell number
under serum deprivation. Values are expressed
as percentage of cell survival as compared to
serum (5% fetal calf serum) treatment. N 5 8
per group. Abbreviations are: DSF, vehicle;
HGF, human recombinant HGF (1, 10, 100 ng/
ml) added to epithelial cells maintained in
DSF; VEGF, human recombinant VEGF (100
ng/ml) added to epithelial cells maintained in
DSF; FGF, human recombinant bFGF (100
ng/ml) added to epithelial cells maintained in
DSF. **P , 0.01 versus serum (5% fetal calf
serum) treatment, #P , 0.05, ##P , 0.01
versus DSF.
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Prevention of apoptosis by HGF was also confirmed using
LLC-PK1 cells assessed by Hoechst staining (Fig. 5).
To examine the therapeutic value of HGF as gene
therapy in epithelial injury, transfection of human HGF
gene was also examined. Rat epithelial cells transfected
with the human HGF expression vector synthesized and
secreted immunoreactive HGF. The accumulation of im-
munoreactive human HGF was readily detected in condi-
tioned medium from epithelial cells transfected with HGF
expression vector, but not in conditioned medium from
untransfected cells or cells transfected with control vector
(untransfected; NS; control, NS; HGF, 0.865 6 0.056
ng/106 cells/24 hr, P , 0.01). The autocrine influence of
transfection of HGF vector on epithelial injury is shown in
Figure 6. Transfection of epithelial cells with the control
expression vector did not alter cell number, compared with
cell number in untransfected epithelial cells. However,
transfection of human HGF vector attenuated cell death
caused by serum deprivation (untransfected, 47,600 6
4000; control vector, 50,600 6 1900; HGF vector, 57,400 6
3200 cells/well, P , 0.01 vs. control vector and untrans-
fected). Moreover, the number of apoptotic cells in cells
transfected with HGF expression vector was significantly





Fig. 3. (A) Morphological changes in nuclei of
rat epithelial cells (NRK-52E) treated with
serum deprivation. Epithelial cells maintained
in DSF exhibited the characteristic features of
cell shrinkage, membrane blebbing and
rounding, typical of apoptotic death. rHGF as
well as serum treatment attenuated these
morphological changes. Abbreviations are: FCS,
epithelial cells treated with 5% fetal calf serum;
serum-free, epithelial cells maintained in DSF;
rHGF, epithelial cells treated with DSF
medium and human rHGF (100 ng/ml) added
to epithelial cells maintained in DSF. **P ,
0.01 versus serum (5% fetal calf serum)
treatment, #P , 0.05, ##P , 0.01 versus DSF.
(B and C, opposite page) Protective effects of
exogenously added HGF and VEGF on
apoptosis of rat epithelial cells (NRK-52E)
under serum deprivation at 48 hours (B) and 96
hours (C) assessed by Hoechst staining. Values
are expressed as percentage of apoptotic cells.
N 5 8 per group. Abbreviations are: DSF,
vehicle added to epithelial cells maintained in
DSF; rHGF, human rHGF (10 and 100 ng/ml)
added to epithelial cells maintained in DSF; 5%
FCS, 5% fetal calf serum added to epithelial
cells. **P , 0.01 versus DSF.
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vector (P , 0.01; Fig. 6). The prevention of apoptosis by
transfection of HGF vector was similar to that obtained by
addition of 10% fetal calf serum.
Protective action on human endothelial cells
As previously reported, HGF also has a protective action
against endothelial injury [32, 34]. Therefore, we further
examined the protective actions of HGF against apoptosis
of endothelial cells. Under basal conditions, human rHGF
as well as VEGF increased the number of endothelial cells
in a dose-dependent manner (Fig. 7A). Our previous study
showed that the signal transduction of HGF is different
from that of VEGF [33]. Therefore, we tested the effects of
HGF and VEGF on the growth of endothelial cells under
TNF-a treatment, which is known to mediate apoptosis [35,
36]. Incubation with TNF-a resulted in a decrease in DNA
synthesis of endothelial cells (Fig. 7B). Importantly, the
addition of human rHGF also significantly attenuated the
decrease in DNA synthesis induced by TNF-a, and was
similar to 10% FCS. In contrast, VEGF failed to show an
attenuation of the decrease in DNA synthesis (P , 0.01),
whereas VEGF stimulated basal endothelial cell growth.
The protective action of HGF was also examined under
dexamethasone treatment, as dexamethasone is also known
to be a mediator of endothelial injury through apoptosis
[37]. Treatment with dexamethasone also resulted in a
decrease in DNA and RNA synthesis of endothelial cells
(Fig. 8). In contrast, the addition of human rHGF resulted
in attenuation of the decrease in DNA and RNA synthesis
induced by dexamethasone treatment (P , 0.05).
Role of hepatocyte growth factor in the regulation of
epithelial cells
Hepatocyte growth factor was detected in the condi-
tioned medium of rat mesangial cells by EIA (0.23 6 0.01
Fig. 4. DNA fragmentation in rat epithelial cells (NRK-52E) treated with
rHGF and rVEGF under serum deprivation at 96 hours assessed by DNA
fragmentation assay (absorbance at OD 690 nm). N 5 6 per group.
Abbreviations are: DSF, vehicle; HGF, human rHGF (10 and 100 ng/ml)
added to epithelial cells maintained in DSF; VEGF, human recombinant
VEGF (100 ng/ml) added to epithelial cells maintained in DSF. **P ,
0.01 versus DSF.
Fig. 5. Protective effects of exogenously added HGF and bFGF on
apoptosis of porcine epithelial cells (LLC-PK1) under serum deprivation
at 96 hours assessed by Hoechst staining. Values are expressed as
percentage of apoptotic cells. N 5 8 per group. Abbreviations are: DSF,
vehicle added to epithelial cells maintained in DSF; rHGF, human rHGF
(1 and 10 ng/ml) added to epithelial cells maintained in DSF; bFGF,
human bFGF (1 and 10 ng/ml) added to epithelial cells maintained in
DSF. **P , 0.01 versus DSF, ##P , 0.01 versus rHGF 1 ng/ml.
Fig. 3. Continued.
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ng/106 cells/24 hr), and was consistent with the previous
findings [17]. On the other hand, we failed to detect
immunoreactive HGF in the culture medium of rat epithe-
lial cells (NRK-52E) by EIA. In contrast, the presence of its
specific functional receptor (c-met) was readily detected by
RT-PCR in both rat (NRK-52E) and porcine epithelial
cells (LLC-PK1; Fig. 9). Given the presence of a local HGF
system in mesangial cells, we hypothesized that local HGF
production by mesangial cells may regulate epithelial cells.
Using a co-culture system, we further examined this hy-
pothesis that local HGF secretion from mesangial cells
regulates the growth of epithelial cells. Co-culture of rat
mesangial cells with rat epithelial cells (NRK-52E) resulted
in a significant increase in cell number (P , 0.01; Fig. 10).
Co-incubation of anti-rat HGF antibody in a co-culture
system of rat mesangial cells with NRK-52E significantly
abolished the mitogenic activity of conditioned medium
from mesangial cells (P , 0.01). Moreover, co-culture of
rat mesangial cells with porcine tubular epithelial cells
(LLC-PK1) also resulted in a significant increase in number
of LLC-PK1 [co-culture (2), 0.177 6 0.004 vs. co-culture
(1), 0.192 6 0.005; P , 0.01].
DISCUSSION
The concept of the local control of renal function by
locally synthesized compounds has been recently described.
It has been hypothesized that locally synthesized growth
factors (such as, TGF-b, bFGF) and multiple endothelium-
derived substances (PGI2, NO, CNP) also have profound
influences on renal function [10–15]. Moreover, following
mesangial injury, locally synthesized and/or down-regulated
cytokines and growth factors contribute to the injury of
endothelial and epithelial cells [38–41]. These local sys-
tems appear to be independently regulated by regional
factors and may play important pathophysiologic roles.
Thus, repair of epithelial and endothelial cells may have
therapeutic actions in the pathogenesis of renal disease.
From this viewpoint, HGF would be of interest, as HGF
has many functions in the cells of target organs including
the kidney [6–9]. Administration of rHGF prevented acute
renal failure and accelerated renal regeneration in mice
Fig. 6. Protective effects of transfected HGF cDNA on number of apo-
ptotic cells in NRK-52E cells. Abbreviations are: DSF, untransfected cells;
CV, cells transfected with control vector; HGF, cells transfected with
human HGF vector; 10% FCS, cells treated with 10% FCS. N 5 6 per
group. **P , 0.01 versus DSF, ##P , 0.01 versus CV.
Fig. 7. (A) Effects of exogenously added HGF and VEGF on human
endothelial cell number. N 5 8 per group. Abbreviations are: DSF,
vehicle; HGF, human recombinant HGF (10 and 100 ng/ml) added to
endothelial cells; VEGF, human recombinant VEGF (10 and 100 ng/ml)
added to endothelial cells; FCS, 10% FCS added to endothelial cells.
**P , 0.01 versus vehicle. (B) Effect of exogenously added HGF and
VEGF on human endothelial DNA synthesis under TNF-a treatment.
N 5 8 per group. Abbreviations are: DSF, vehicle; HGF, human recom-
binant HGF (10 ng/ml) added to endothelial cells; VEGF, human
recombinant VEGF (10 ng/ml) added to endothelial cells; TNF, human
recombinant tumor necrosis factor-a (20 nM) added to endothelial cells;
FCS, 10% fetal calf serum added to endothelial cells. **P , 0.01 versus
DSF, #P , 0.05 versus TNF.
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treated with HgCl2 and cisplatin [7, 9]. Recent findings also
show that HGF may play an important role in tissue
regeneration [3–9]. Consistent with the previous findings
[17, 32, 33], our present results demonstrated that HGF can
stimulate growth of epithelial and endothelial cells (Fig. 1),
while it has no mitogenic action on mesangial cell growth.
Therefore, we examined the protective action of HGF
against epithelial cell injury induced by serum deprivation,
which is a known mediator of apoptosis in epithelial cells
[34, 35]. Of interest, HGF could abrogate the death of
epithelial cells mediated by serum deprivation (Figs. 1 and
2). In addition, HGF was shown to prevent apoptosis of
epithelial cells induced by serum deprivation assessed by
two different kinds of morphological examination and
DNA fragmentation assay. HGF should be classed as a new
member of the growth factors with anti-cell death actions in
epithelial cells through the inhibition of apoptosis. The
mechanisms by which HGF prevented epithelial cell death
mediated by the conditions in this study are unclear. HGF
is known to stimulate phosphatidylinositol-37-kinase
(PI3K), protein tyrosine phosphatase 2, phospholipase C-r,
pp60c-src, grb2/hSos1, rho and ras [2–4, 42–45]. The activa-
tion of these signal transduction pathways suggests that
HGF will act to prevent cell death.
On the other hand, secretion of local HGF from mesan-
gial cells also maintains growth of endothelial cells [17].
Numerous papers have reported the loss of vasodilating
properties of resistance vessels in chronic renal failure
patients [13–15]. As previously reported [33], HGF stimu-
lated exclusively the growth of endothelial cells, but not
VSMC. Therefore, we also examined whether HGF has a
protective action on endothelial function in various condi-
tions such as TNF-a and dexamethasone treatment, which
are known to induce apoptosis [35–37]. Interestingly, rHGF
attenuated the endothelial injury induced by TNF-a and
dexamethasone treatment (Fig. 1B), suggesting that HGF
in part may play a pivotal role in endothelial regulation.
What is the role of local renal HGF system in the
maintenance of renal function? Mesangial cells, but not
epithelial cells, secrete HGF, while epithelial cells have its
specific receptor, c-met (Fig. 9). To examine the new
concept that local production of HGF, which stimulates
growth of epithelial cells but not mesangial cells, maintains
growth of epithelial cells, the effects of local HGF produc-
tion from mesangial cells on epithelial cell growth were
studied using a co-culture system. Co-culture of mesangial
cells with epithelial cells resulted in a significant increase in
the number of epithelial cells, which was abolished by
co-incubation with neutralizing anti-HGF antibody. Since
addition of neutralizing anti-HGF antibody could not com-
pletely abolish the mitogenic action of co-culture with
mesangial cells, other substances may also work to maintain
the cell-cell interactions, in addition to HGF. Our previous
study demonstrated a marked reduction of local HGF
expression in mesangial cells by TGF-b and Ang II treat-
ment [17]. Taken together, down-regulation of local HGF
secretion from mesangial cells by TGF-b and Ang II may
result in renal (epithelial and endothelial) dysfunction.
Indeed, our previous report showed a significant decrease
in local renal HGF level in spontaneously hypertensive rats
as compared to normotensive Wistar-Kyoto rats [45]. The
break of the paracrine-loop of HGF, which maintains
epithelial and endothelial cell growth, by TGF-b and/or
Ang II may result in a dysfunction of the cell-cell regulation
Fig. 8. Effect of exogenously added recombinant HGF on human endo-
thelial cell (A) DNA and (B) RNA synthesis under dexamethasone
treatment. N 5 8 per group. Abbreviations are: DSF, vehicle; HGF,
human recombinant HGF (10 ng/ml) added to endothelial cells; DX,
dexamethasone (1027 M) added to endothelial cells. **P , 0.01 versus
DSF, #P , 0.05 versus TNF.
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in the kidney, which in turn may accelerate the develop-
ment of renal disease such as glomerulonephritis.
Overall, these results demonstrate that local production
of HGF from mesangial cells may maintain epithelial and
endothelial cell growth through its anti-apoptotic action. As
local HGF secretion from mesangial cells was negatively
regulated by Ang II and TGF-b [17], a decrease in local
renal HGF production might be related to the dysfunction
of renal cells in renal disease.
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basic fibroblast growth factor; BSS, balanced salt solution; CNP, C-type
natriuretic peptide; DMEM, Dulbecco’s modified Eagle’s medium; DSF,
defined serum-free medium; H33342, membrane permeable dye; HGF,
hepatocyte growth factor; HMG, high mobility group; HVJ-liposomes,
hemagglutinating virus of Japan-liposomes; LLC-PK1, porcine tubular
epithelial cells; MC, mesangial cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5,-diphenyl tetrazolium bromide; NO, nitric oxide; NRK-52E, rat epi-
thelial cell line; PBS, phosphate buffered saline; PGI2, prostaglandin I2;
PI, propium iodide; PI3K, phosphatidylinositol-37-kinase; rHGF, recom-
binant hepatocyte growth factor; RT-PCR, reverse transcription-poly-
merase chain reaction; TCA, trichloroacetic acid; TGF-b, transforming
growth factor-b; TNF-a, tumor necrosis factor alpha; VEGF, vascular
endothelial growth factor; VSMC, vascular smooth muscle cells; WST-1,
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